Literature DB >> 14727844

Quantitative analysis of thymosin alpha1 in human serum by LC-MS/MS.

C W Tuthill1, A Rudolph, Y Li, B Tan, T J Fitzgerald, S R Beck, Y X Li.   

Abstract

A high performance liquid chromatography with tandem mass spectrometry (LC-MS/MS) method was developed to measure the thymosin alpha 1 (Talpha1) concentration in human serum. Tá1 in human serum was determined by solid phase extraction and reverse phase LC-MS/MS. The high-performance liquid chromatography (HPLC) system interfaced with the MS/MS system with a Turbo Ion spray interface. Positive ion detection and multiple reaction monitoring (MRM) mode were used for this human serum quantitation. Eight different concentration standards were used to establish the detection range. Six quality control (QC) and 2 matrix blanks were checked by calibration curves performed on the same day. The lower quantitation limit was 0.5 ng/mL Talpha1 in human serum. Calibration curves were established between 0.5 to 100 ng/mL by weighted linear regression. The correlation coefficients for different days were 0.9955 or greater. Quantitation of Talpha1 by the LC-MS/MS method is fast, accurate, and precise.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 14727844      PMCID: PMC2784822          DOI: 10.1208/pt010211

Source DB:  PubMed          Journal:  AAPS PharmSciTech        ISSN: 1530-9932            Impact factor:   3.246


  23 in total

1.  Thymosin-alpha1 stimulates maturation of CD34+ stem cells into CD3+4+ cells in an in vitro thymic epithelia organ coculture model.

Authors:  A P Knutsen; J J Freeman; K R Mueller; S T Roodman; J D Bouhasin
Journal:  Int J Immunopharmacol       Date:  1999-01

2.  The chemistry and biology of thymosin. I. Isolation, characterization, and biological activities of thymosin alpha1 and polypeptide beta1 from calf thymus.

Authors:  T L Low; G B Thurman; M McAdoo; J McClure; J L Rossio; P H Naylor; A L Goldstein
Journal:  J Biol Chem       Date:  1979-02-10       Impact factor: 5.157

3.  Serum levels of immunoreactive thymosin alpha 1 and thymosin beta 4 in large cohorts of healthy adults.

Authors:  F E Weller; U Shah; G D Cummings; P B Chretien; M G Mutchnick
Journal:  Thymus       Date:  1992-02

4.  Efficacy of thymosin alpha1 in patients with chronic hepatitis B: a randomized, controlled trial.

Authors:  R N Chien; Y F Liaw; T C Chen; C T Yeh; I S Sheen
Journal:  Hepatology       Date:  1998-05       Impact factor: 17.425

5.  Thymosin alpha 1 antagonizes dexamethasone and CD3-induced apoptosis of CD4+ CD8+ thymocytes through the activation of cAMP and protein kinase C dependent second messenger pathways.

Authors:  C A Baumann; M Badamchian; A L Goldstein
Journal:  Mech Ageing Dev       Date:  1997-03       Impact factor: 5.432

6.  Combination thymosin alpha 1 and lymphoblastoid interferon treatment in chronic hepatitis C.

Authors:  G Rasi; D DiVirgilio; M G Mutchnick; F Colella; P Sinibaldi-Vallebona; P Pierimarchi; B Valli; E Garaci
Journal:  Gut       Date:  1996-11       Impact factor: 23.059

7.  Combination therapy with thymosin alpha1 and interferon for the treatment of chronic hepatitis C infection: a randomized, placebo-controlled double-blind trial.

Authors:  K E Sherman; M Sjogren; R L Creager; M A Damiano; S Freeman; S Lewey; D Davis; S Root; F L Weber; K G Ishak; Z D Goodman
Journal:  Hepatology       Date:  1998-04       Impact factor: 17.425

8.  Pharmacokinetics of thymosin alpha1 after subcutaneous injection of three different formulations in healthy volunteers.

Authors:  K L Rost; W Wierich; F Masayuki; C W Tuthill; D L Horwitz; W M Herrmann
Journal:  Int J Clin Pharmacol Ther       Date:  1999-01       Impact factor: 1.366

9.  A randomized controlled trial of thymosin-alpha1 versus interferon alfa treatment in patients with hepatitis B e antigen antibody--and hepatitis B virus DNA--positive chronic hepatitis B.

Authors:  P Andreone; C Cursaro; A Gramenzi; C Zavagliz; I Rezakovic; E Altomare; R Severini; J S Franzone; O Albano; G Ideo; M Bernardi; G Gasbarrini
Journal:  Hepatology       Date:  1996-10       Impact factor: 17.425

10.  Low thymosin alpha-1 concentrations in patients chronically infected with the hepatitis B virus.

Authors:  K E Sherman; C C Jones; A L Goldstein; P H Naylor
Journal:  Viral Immunol       Date:  1991       Impact factor: 2.257

View more
  4 in total

Review 1.  Candidate-based proteomics in the search for biomarkers of cardiovascular disease.

Authors:  Leigh Anderson
Journal:  J Physiol       Date:  2004-12-20       Impact factor: 5.182

Review 2.  A human proteome detection and quantitation project.

Authors:  N Leigh Anderson; Norman G Anderson; Terry W Pearson; Christoph H Borchers; Amanda G Paulovich; Scott D Patterson; Michael Gillette; Ruedi Aebersold; Steven A Carr
Journal:  Mol Cell Proteomics       Date:  2009-01-07       Impact factor: 5.911

3.  Evaluation of pharmacokinetics of bioreducible gene delivery vectors by real-time PCR.

Authors:  Qing-Hui Zhou; Chao Wu; Devika Soundara Manickam; David Oupický
Journal:  Pharm Res       Date:  2009-02-25       Impact factor: 4.200

Review 4.  Thymosin alpha 1: A comprehensive review of the literature.

Authors:  Asimina Dominari; Donald Hathaway Iii; Krunal Pandav; Wanessa Matos; Sharmi Biswas; Gowry Reddy; Sindhu Thevuthasan; Muhammad Adnan Khan; Anoopa Mathew; Sarabjot Singh Makkar; Madiha Zaidi; Michael Maher Mourad Fahem; Renato Beas; Valeria Castaneda; Trissa Paul; John Halpern; Diana Baralt
Journal:  World J Virol       Date:  2020-12-15
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.